UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~February~~March 918, 2026

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37939	45-4497941
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2450 Holcombe Blvd, TMC Partners Office 1.311

Houston, Texas

77021

(Address of principal executive offices)

(Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 52.0802 ~~Shareholder~~Results ~~Director~~of ~~Nominations~~Operations and Financial Condition.

On ~~February 9~~ March 18, 2026, ~~the Board of Directors of~~ Marker Therapeutics, Inc. (the “Company”) ~~determined~~reported itfinancial isresults infor the ~~best interest of the Company to schedule Company’s~~year ~~2026~~ended ~~Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1~~December 31, ~~2026. Because the date of the 2026 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s~~ 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), in accordance with Rule 14a−18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing stockholders of such change and ~~that,~~other ~~accordingly,~~recent acorporate ~~new~~updates. ~~deadline~~A ~~has~~copy ~~been set for submission~~ of ~~proposals by Stockholders intended to be included in~~ the ~~Company’s~~press ~~2026~~release proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the 2026 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act must be received by the Company on or before March 9, 2026, which the Company believes is afurnished ~~reasonable~~as ~~time before it expects to begin to print and send its proxy materials~~Exhibit 99.1 ~~Stockholders must deliver the proposals or nominations~~ to ~~the Company’s principal executive offices at the~~this ~~following~~report ~~address: Marker Therapeutics, Inc., Attn: Corporate Secretary, 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021. The record date, time~~ and ~~location~~incorporated ofby ~~the 2026 Annual Meeting will be as set forth in the Company’s proxy statement for the 2026 Annual Meeting~~reference.

The information in this Item 92.0102 of this Current Report on Form 8-K (including Exhibit 99.1) ~~Financial~~is ~~Statements~~furnished and ~~Exhibits~~shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

~~(d)~~Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

(d) Exhibits.

SIGNATURES

Exhibit No.	Description

99.1	Press Release dated March 18, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

~~Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURES

	Marker Therapeutics, Inc.
Dated: February 9, 2026	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Marker Therapeutics, Inc.

Dated: March 18, 2026	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer

Filing Compare · Marker Therapeutics, Inc.